Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
Rearranged during transfection (RET) is a protooncogene that encodes for receptor tyrosine
kinase with downstream effects on multiple cellular pathways. Activating RET alterations can …
kinase with downstream effects on multiple cellular pathways. Activating RET alterations can …
[HTML][HTML] The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review
P Christopoulos - Chinese Clinical Oncology, 2024 - cco.amegroups.org
Methods: A literature search for randomized phase 2/3 trials on the treatment of early-stage
NSCLC was performed based on PubMed and the content on major oncology congresses …
NSCLC was performed based on PubMed and the content on major oncology congresses …
The evolving landscape of tissue‐agnostic therapies in precision oncology
Tumor‐agnostic therapies represent a paradigm shift in oncology by altering the traditional
means of characterizing tumors based on their origin or location. Instead, they zero in on …
means of characterizing tumors based on their origin or location. Instead, they zero in on …
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
JW Goldman, LM Sholl, S Dacic, MC Fishbein… - Frontiers in …, 2023 - frontiersin.org
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during
transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell …
transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell …
The evolving role for systemic therapy in resectable non-small cell lung cancer
MJ Grant, GA Woodard… - Hematology/Oncology …, 2023 - hemonc.theclinics.com
During the last 2 decades, the understanding of non-small cell lung cancer (NSCLC) has
evolved from a purely histologic classification system to a more complex model synthesizing …
evolved from a purely histologic classification system to a more complex model synthesizing …
Advances in the diagnosis and treatment of a driving target: RET rearrangements in non-small-cell lung cancer (NSCLC) especially in china
T Li, WY Yang, TT Liu, Y Li, L Liu… - … in Cancer Research …, 2023 - journals.sagepub.com
In the era of precision medicine, with the deepening of the research on malignant tumor
driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small …
driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small …
Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
HY Park, JH Park, MG Shin, SJ Han, YS Ji… - Frontiers in …, 2023 - frontiersin.org
Background Cancer recurrence remains a significant problem, and most postoperative
recurrences of non-small cell lung cancer (NSCLC) develop within 5 years after resection …
recurrences of non-small cell lung cancer (NSCLC) develop within 5 years after resection …
Selpercatinib as the guardian of the central nervous system for patients with RET fusion-positive NSCLC?
SCM Lau, SHI Ou - Journal of Thoracic Oncology, 2023 - jto.org
The incidences of central nervous system (CNS) metastasis among newly diagnosed
treatment-naive patients with RET-positive (+) NSCLC enrolled into the registrational …
treatment-naive patients with RET-positive (+) NSCLC enrolled into the registrational …
Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition
Selective RET inhibitors have shown promise in thyroid cancer (TC) and nonsmall cell lung
cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although …
cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although …
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer
(NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers …
(NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers …